专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007035028A1 NOVEL RESINATE COMPLEX OF S-CLOPIDOGREL AND PRODUCTION METHOD THEREOF 审中-公开
标题翻译：新型树脂复合材料及其生产方法
公开(公告)号：WO2007035028A1
公开(公告)日：2007-03-29
申请号：PCT/KR2006/003346
申请日：2006-08-24
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , SHIN, Hee Jong , KI, Min Hyo , CHOI, Mee Hwa
发明人： SHIN, Hee Jong , KI, Min Hyo , CHOI, Mee Hwa
IPC分类号： C07D495/04
CPC分类号： A61K31/4365 , A61K47/585 , C07D495/04
摘要： The present invention is a novel resinate complex of (+)-clopidogrel optical isomer, wherein the (+)-clopidogrel isomer is bounded to a water-soluble cation exchange resin having sulfonic acid groups. The novel resinate complex has recognized some advantages in that (1) its chemical structure is stable, and (2) it can be formulated into a solid form that may provide taste-masking capabilities associated with bitter drugs (e.g., strong irritation, bitterness and sour taste), thus requiring no drink of water.
摘要翻译：本发明是（+） - 氯吡格雷旋光异构体的新型树脂酸复合物，其中（+） - 氯吡格雷异构体与具有磺酸基的水溶性阳离子交换树脂结合。新型树脂酸复合物已经认识到一些优点：（1）其化学结构是稳定的，和（2）它可以配制成固体形式，其可以提供与苦味药相关的味道掩蔽能力（例如，强刺激，苦味和酸味），因此不需要饮用水。

2. 发明申请

WO2006080780A1 PHARMACEUTICAL COMPOSITIONS CONTAINING BISPHOSPHONATE FOR IMPROVING ORAL ABSORPTION 审中-公开
标题翻译：含有二磷酸酯的药物组合物，用于改善口服吸收
公开(公告)号：WO2006080780A1
公开(公告)日：2006-08-03
申请号：PCT/KR2006/000013
申请日：2006-01-03
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa , LEE, Jin-Woo
发明人： SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa , LEE, Jin-Woo
IPC分类号： A61K31/663 , A61P19/10
CPC分类号： A61K9/2054 , A61K9/0095 , A61K9/1623 , A61K9/1652 , A61K9/2013 , A61K9/205 , A61K9/2059 , A61K31/663
摘要： Provided is a pharmaceutical composition having improved oral absorption of a bisphosphonate drug, comprising at least one active substance selected from bisphosphonate drugs having non-permeability to a lipid biomembrane due to ionization and high water-solubility in vivo and having bioavailability of less than 10%, and at least one selected from biocompatible water-soluble chitosan, as essential ingredients.
摘要翻译：本发明提供了具有改善的双膦酸盐药物口服吸收的药物组合物，其包含至少一种活性物质，所述活性物质由于离子化而对脂质生物膜具有非渗透性，并且在体内具有高水溶性，并且具有小于10％的生物利用度，，和选自生物相容性水溶性壳聚糖中的至少一种作为必需成分。

3. 发明申请

WO2004052405A1 ORAL FORMULATIONS FOR POORLY ABSORPTIVE HYDROPHILIC DRUGS 审中-公开
标题翻译：不良吸收性水解药物的口服制剂
公开(公告)号：WO2004052405A1
公开(公告)日：2004-06-24
申请号：PCT/KR2003/002700
申请日：2003-12-10
申请人： CHONG KUN DANG PHARMACEUTICAL CORP. , MC TECHNOLOGIES, INC. , HONG, CHUNG-IL , SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa
发明人： HONG, CHUNG-IL , SHIN, Hee-Jong , KI, Min-Hyo , CHOI, Mee-Hwa
IPC分类号： A61K47/48
CPC分类号： B82Y5/00 , A61K47/6929
摘要： Disclosed herein is a pharmaceutical composition for oral absorption of polar drugs. The composition consists essentially of (a) at least one polar active substance having a bioavailability of less than 30% which is poorly absorptive through lipid membranes because of its high hydrophilicity and charged ion; (b) at least one organic alkalizing agent having an amino acid or polyol structure which shows alkalinity in aqueous solution and is ionically bonded to the polar active substance; and (c) at least one surfactant having a C 6-18 fatty acid structure which has an HLB of 4 to 18. Alternatively, the composition consists essentially of (d) at least one organic alkalizing agent having the characteristics of both the organic alkalizing agent and the surfactant instead of the organic alkalizing agent and the surfactant. The composition enables polar active drugs to penetrate the gastro- intestinal membrane and oral dosage forms to be substituted for injections.
摘要翻译：本文公开了用于口服吸收极性药物的药物组合物。所述组合物基本上由（a）至少一种具有小于30％的生物利用度的极性活性物质组成，其通过脂质膜难以吸收，因为它具有高亲水性和带电离子; （b）至少一种具有在水溶液中显示碱度并与极性活性物质离子键合的氨基酸或多元醇结构的有机碱化剂; 和（c）至少一种具有HLB为4至18的C 6-18脂肪酸结构的表面活性剂。或者，组合物基本上由（d）至少一种具有两种有机碱化剂的有机碱化剂和表面活性剂代替有机碱化剂和表面活性剂。该组合物可使极性活性药物穿透胃肠膜和口服剂型以代替注射。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式